Literature DB >> 32714518

The Current Status of US and Global Access to Direct-Acting Antiviral Regimens for Hepatitis C Virus Infection.

Camilla S Graham1.   

Abstract

Watch an interview with the author.
© 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2020        PMID： 32714518      PMCID： PMC7373775          DOI： 10.1002/cld.925

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


  5 in total

Review 1.  New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.

Authors:  Stéphane Chevaliez; Jean-Michel Pawlotsky
Journal:  J Hepatol       Date:  2018-05-23       Impact factor: 25.083

2.  A path to eradication of hepatitis C in low- and middle-income countries.

Authors:  Camilla S Graham; Tracy Swan
Journal:  Antiviral Res       Date:  2015-01-20       Impact factor: 5.970

Review 3.  Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.

Authors:  Anne C Spaulding; Madeline G Adee; Robert T Lawrence; Jagpreet Chhatwal; William von Oehsen
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

4.  Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Authors:  Andrew Hill; Saye Khoo; Joe Fortunak; Bryony Simmons; Nathan Ford
Journal:  Clin Infect Dis       Date:  2014-01-06       Impact factor: 9.079

5.  Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?

Authors:  Yibeltal Assefa; Peter S Hill; Anar Ulikpan; Owain D Williams
Journal:  Global Health       Date:  2017-09-13       Impact factor: 4.185
  5 in total
  3 in total

1.  Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.

Authors:  Sarah J Willis; H Nina Kim; Chad J Achenbach; Edward R Cachay; Katerina A Christopoulos; Heidi M Crane; Ricardo A Franco; Christopher B Hurt; Mari M Kitahata; Richard D Moore; Michael J Silverberg; Phyllis C Tien; Daniel Westreich; Julia L Marcus
Journal:  HIV Med       Date:  2021-12-23       Impact factor: 3.094

2.  Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.

Authors:  Ashish Goyal; Alex Churkin; Danny Barash; Scott J Cotler; Amir Shlomai; Ohad Etzion; Harel Dahari
Journal:  Open Forum Infect Dis       Date:  2022-03-22       Impact factor: 4.423

3.  Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.

Authors:  Lewis Beer; Sarah Inglis; Amy Malaguti; Christopher Byrne; Christian Sharkey; Emma Robinson; Kirsty Gillings; Andrew Radley; Adrian Hapca; Brian Stephens; John Dillon
Journal:  J Viral Hepat       Date:  2022-05-26       Impact factor: 3.517
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.